title: Initial experience and clinical evaluation of the Absorb bioresorbable vascular scaffold (BVS) in real-world practice: the AMC Single Centre Real World PCI Registry.
abstract: OBJECTIVE
  To report procedural and midterm clinical outcomes after the use of the second-generation Absorb everolimus-eluting bioresorbable vascular scaffold (Absorb BVS) in a real-world percutaneous coronary intervention (PCI) registry.
  
  
  RESULTS
  All patients assigned to treatment with the Absorb BVS in the Academic Medical Center, Amsterdam, between August 2012 and August 2013 were included in a prospective registry. A total of 135 patients were included in the study, including 53 (39%) acute coronary syndrome (ACS) patients (13% ST-segment elevation myocardial infarction [STEMI]). In total 159 lesions were treated, including 102 (62%) with a type B2 or C classification. Pre- and post-procedural quantitative coronary angiography (QCA) analyses showed an acute gain of 1.37±0.53 mm. An angiographic success rate was achieved in 152 (96%) of the lesions. Six-month follow-up was available in 97% of the patients. Six-month cumulative target vessel failure (composite of all-cause mortality, any myocardial infarction [MI] and target vessel revascularisation [TVR]) rate was 8.5%, including a 3.0% MI, 3.0% definite scaffold thrombosis, 6.3% target lesion revascularisation, and an 8.5% TVR rate.
  
  
  CONCLUSIONS
  The use of the Absorb BVS in a cohort reflecting daily clinical practice is feasible and associated with good procedural safety and angiographic success rate. In addition, six-month follow-up is associated with acceptable clinical outcomes.
authors.affiliation: AMC Heartcenter, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
authors.forename: Robin P
authors.initials: RP
authors.lastname: Kraak
authors.forename: Mariëlla E C J
authors.initials: ME
authors.lastname: Hassell
authors.forename: Maik J
authors.initials: MJ
authors.lastname: Grundeken
authors.forename: Karel T
authors.initials: KT
authors.lastname: Koch
authors.forename: Jose P S
authors.initials: JP
authors.lastname: Henriques
authors.forename: Jan J
authors.initials: JJ
authors.lastname: Piek
authors.forename: Jan
authors.initials: J
authors.lastname: Baan
authors.forename: Marije M
authors.initials: MM
authors.lastname: Vis
authors.forename: E Karin
authors.initials: EK
authors.lastname: Arkenbout
authors.forename: Jan G P
authors.initials: JG
authors.lastname: Tijssen
authors.forename: Robbert J
authors.initials: RJ
authors.lastname: de Winter
authors.forename: Joanna J
authors.initials: JJ
authors.lastname: Wykrzykowska
mesh_terms: D020341:Absorbable Implants; D054058:Acute Coronary Syndrome / Q000188:drug therapy / Q000601:surgery*; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000401:mortality; D015331:Cohort Studies; D023921:Coronary Stenosis / Q000188:drug therapy / Q000601:surgery*; D054855:Drug-Eluting Stents; D000068338:Everolimus / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy / Q000453:epidemiology / Q000601:surgery*; D009426:Netherlands; D062645:Percutaneous Coronary Intervention / Q000295:instrumentation; D011446:Prospective Studies; D012042:Registries; D012086:Reoperation; D054457:Tissue Scaffolds; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D000068338:Everolimus